EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Henagliflozin enhances frontal neural activation and cognitive function versus gliclazide in type 2 diabetes patients with mild cognitive impairment: A 16-week randomized controlled trial

Yining Chao, Jingyi Jiao, Bing Zhang, Jing Sun, Xuewei Tong, Huijie Yang, Tianyu Wu, Zhou Zhang, Yan Bi

Journal of Endocrinological Investigation · 2026

DOI: 10.1007/s40618-025-02775-2 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Endocrinological Investigation, 2026. Verfasst von Yining Chao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Endocrine and Metabolic Disease Medical Center, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanj…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Gliclazide, Cognitive Dysfunction, Cognition. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, the National Natural Science Foundation of China Grant Awards, YLHR Diabetes Metabolism Research Fund Project of China International Medical Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: Head-to-head comparisons of neuroprotective efficacy of glucose-lowering agents remain lacking in type 2 diabetes (T2D) patients with mild cognitive impairment (MCI). Here, we investigated the effects of henagliflozin or gliclazide on brain functional alterations and cognitive changes in these patients. MATERIALS AND METHODS: Twenty-four T2D patients with MCI were randomized (1:1) to receive henagliflozin or gliclazide treatment for 16 weeks. We assessed anthropometric and metabolic profiling, global and domain-specific cognitive testing, olfactory performance, and structural and functional magnetic resonance imaging (fMRI) at baseline and follow-up. The primary outcome was the between-group difference in odor-task fMRI activation at week 16. RESULTS: Treatment with henagliflozin for 16 weeks significantly increased odor-task fMRI activation in the left frontal white matter (Gaussian random field corrected) compared to gliclazide. Subsequent seed-based analysis revealed reduced functional connectivity to the left middle frontal gyrus, suggesting altered frontal network integration. These functional brain alterations were accompanied by significant improvements in global cognition (Montreal Cognitive Assessment [MoCA]: Δ + 2.1 vs. Δ − 0.2, P = 0.002) and delayed memory (Δ + 5.7 vs. Δ − 2.7, P = 0.012) in henagliflozin compared to gliclazide. Exploratory analyses suggested potential associations between concomitant metabolic improvements and cognitive/neuroimaging alterations, which merit further investigation. CONCLUSIONS: Our study showed that henagliflozin enhanced frontal brain activity and improved cognition (global and domain-specific: delayed memory) in T2D patients with MCI over 16 weeks, whereas gliclazide did not. These findings highlight the potential of henagliflozin for cognitive protection in this high-risk population. REGISTRATION: ClinicalTrials.gov (NCT06085703).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2GliclazideCognitive DysfunctionCognitionFrontal LobeHumansMaleFemaleMagnetic Resonance ImagingHypoglycemic AgentsAgedMiddle AgedFollow-Up StudiesCognitive EnhancementPrognosis

Stichwörter der Autor:innen

Cognitive functionFunctional magnetic resonance imagingMild cognitive impairmentRandomized controlled trialSGLT2 inhibitorType 2 diabetes

Substanzen

GliclazideHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Endocrinology, Endocrine and Metabolic Disease Medical Center, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • Branch of National Clinical Research Centre for Metabolic Diseases, Nanjing, China.
  • Department of Radiology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • Department of Endocrinology, Endocrine and Metabolic Disease Medical Center, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China.
  • Department of Endocrinology, Endocrine and Metabolic Disease Medical Center, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. zhangzhou@smail.nju.edu.cn.
  • Branch of National Clinical Research Centre for Metabolic Diseases, Nanjing, China. zhangzhou@smail.nju.edu.cn.

Förderung

  • Noncommunicable Chronic Diseases-National Science and Technology Major Project
  • the National Natural Science Foundation of China Grant Awards
  • YLHR Diabetes Metabolism Research Fund Project of China International Medical Foundation
  • the Jiangsu Provincial Medical Key Discipline Cultivation Unit
  • the Natural Science Foundation of Jiangsu Province of China
  • the Nanjing Health Science and Technology Development Project
  • the National Chinese-Western Medicine Clinical Collaboration Project for Major Difficult Diseases
  • the Multidisciplinary Joint Innovation and Tackling New Technology Project from the Affiliated Drum Tower Hospital, Medical School of Nanjing University

Zitieren

APA

Chao, Y., Jiao, J., Zhang, B., Sun, J., Tong, X., Yang, H., Wu, T., Zhang, Z., & Bi, Y. (2026). Henagliflozin enhances frontal neural activation and cognitive function versus gliclazide in type 2 diabetes patients with mild cognitive impairment: A 16-week randomized controlled trial. Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-025-02775-2

Vancouver

Chao Y, Jiao J, Zhang B, Sun J, Tong X, Yang H, et al. Henagliflozin enhances frontal neural activation and cognitive function versus gliclazide in type 2 diabetes patients with mild cognitive impairment: A 16-week randomized controlled trial. Journal of Endocrinological Investigation. 2026. doi:10.1007/s40618-025-02775-2

BibTeX
@article{Chao2026,
  author = {Chao, Yining and Jiao, Jingyi and Zhang, Bing and Sun, Jing and Tong, Xuewei and Yang, Huijie and Wu, Tianyu and Zhang, Zhou and Bi, Yan},
  title = {Henagliflozin enhances frontal neural activation and cognitive function versus gliclazide in type 2 diabetes patients with mild cognitive impairment: A 16-week randomized controlled trial},
  journal = {Journal of Endocrinological Investigation},
  year = {2026},
  doi = {10.1007/s40618-025-02775-2}
}
Kostenlos starten →